Deciphera Pharmaceuticals, Inc. (DCPH)
- Previous Close
14.58 - Open
14.57 - Bid 14.64 x 200
- Ask 14.73 x 100
- Day's Range
14.56 - 15.19 - 52 Week Range
9.90 - 17.73 - Volume
414,272 - Avg. Volume
516,206 - Market Cap (intraday)
1.185B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
-- - EPS (TTM)
-2.29 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.20
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
www.deciphera.com355
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DCPH
Performance Overview: DCPH
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DCPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DCPH
Valuation Measures
Market Cap
1.18B
Enterprise Value
898.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.60
Price/Book (mrq)
3.36
Enterprise Value/Revenue
5.50
Enterprise Value/EBITDA
-4.30
Financial Highlights
Profitability and Income Statement
Profit Margin
-119.34%
Return on Assets (ttm)
-28.43%
Return on Equity (ttm)
-56.29%
Revenue (ttm)
163.36M
Net Income Avi to Common (ttm)
-194.94M
Diluted EPS (ttm)
-2.29
Balance Sheet and Cash Flow
Total Cash (mrq)
306.22M
Total Debt/Equity (mrq)
7.37%
Levered Free Cash Flow (ttm)
-72.79M